Thomas Liu
Baptist Health South Florida · 23 works · 7,308 citations · h-index 13
Top works
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
- Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia
- Multiple Co-primary Endpoints: Medical and Statistical Solutions: A Report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America
- Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic
- Bayesian Meta‐Experimental Design: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
- Regional distribution of carcinogen‐induced colonic neoplasia in the rat
- Efficient Norovirus and Reovirus Replication in the Mouse Intestine Requires Microfold (M) Cells
- AMG 145, a Monoclonal Antibody Against PCSK9, Facilitates Achievement of National Cholesterol Education Program–Adult Treatment Panel III Low-Density Lipoprotein Cholesterol Goals Among High-Risk Patients
- Murine Norovirus Transcytosis across anIn VitroPolarized Murine Intestinal Epithelial Monolayer Is Mediated by M-Like Cells
- Performance of some multiple testing procedures to compare three doses of a test drug and placebo
- Bayesian sequential meta‐analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program
- Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab
- Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals
- PCSK9 INHIBITION-MEDIATED REDUCTION IN TRIGLYCERIDE WITH EVOLOCUMAB IS RELATED TO BASELINE TRIGLYCERIDE LEVELS: AN ANALYSIS FROM 1791 PATIENTS
- Man with ear injury
- Efficacy and Safety of AMG 145, a Fully Human Monoclonal Antibody to PCSK9: Data from Four Phase 2 Studies in Over 1200 Patients
- Resources and strategies for learning infectious diseases pharmacotherapy during advanced pharmacy practice experiences and pharmacy residency
- TWO YEAR ANALYSIS OF THE SAFETY AND TOLERABILITY OF EVOLOCUMAB: THE OSLER-1 STUDY
- Abstract 16196: Impact of Baseline PCSK9 Levels on the Efficacy of Evolocumab, a Monoclonal Antibody Against PCSK9